(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, no 10, , p. 905–911 (ISSN0040-6376 et 1468-3296, PMID28473506, DOI10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le )
H-J Aubin & al., « Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial », Thorax, BMJ Publishing Group Ltd & British Thoracic Society, vol. 63, , p. 717-724 (DOI10.1136/thx.2007.090647, lire en ligne)
(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, no 10, , p. 905–911 (ISSN0040-6376 et 1468-3296, PMID28473506, DOI10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le )
H-J Aubin & al., « Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial », Thorax, BMJ Publishing Group Ltd & British Thoracic Society, vol. 63, , p. 717-724 (DOI10.1136/thx.2007.090647, lire en ligne)
Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20, , p. 46 (ISSN1617-9625, PMID35611069, PMCID9086158, DOI10.18332/tid/146567, lire en ligne, consulté le )
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205, , p. 107631 (ISSN1879-0046, PMID31678838, DOI10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le )
(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, no 10, , p. 905–911 (ISSN0040-6376 et 1468-3296, PMID28473506, DOI10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le )
Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20, , p. 46 (ISSN1617-9625, PMID35611069, PMCID9086158, DOI10.18332/tid/146567, lire en ligne, consulté le )
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205, , p. 107631 (ISSN1879-0046, PMID31678838, DOI10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le )
(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, no 10, , p. 905–911 (ISSN0040-6376 et 1468-3296, PMID28473506, DOI10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le )
(en) Jorenby D E & al., « Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial », JAMA, vol. 296, no 1, , p. 56–63 (PMID16820547)
Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20, , p. 46 (ISSN1617-9625, PMID35611069, PMCID9086158, DOI10.18332/tid/146567, lire en ligne, consulté le )
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205, , p. 107631 (ISSN1879-0046, PMID31678838, DOI10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le )
pubmed.ncbi.nlm.nih.gov
Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20, , p. 46 (ISSN1617-9625, PMID35611069, PMCID9086158, DOI10.18332/tid/146567, lire en ligne, consulté le )
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205, , p. 107631 (ISSN1879-0046, PMID31678838, DOI10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le )
nytimes.com
(en) Stephanie Saul, « F.A.A. Bans Antismoking Drug, Citing Side Effects », New York Times, (lire en ligne, consulté le )